{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T22:55:51Z","timestamp":1795128951699,"version":"4.10.3"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"F. Hoffmann-LaRoche"},{"name":"Janssen, Galapagos and Servier"},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018952","name":"Birmingham Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018952","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Birmingham Clinical Research Facility"},{"name":"National Health Service"},{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004856","name":"Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Primary SS (pSS) is a chronic autoimmune disorder characterized by mucosal dryness and systemic symptoms. We tested the effects of inhibition of cathepsin S using the potent and selective inhibitor RO5459072 on disease activity and symptoms of pSS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a randomized, double-blind, placebo-controlled, parallel-group, Phase IIA study to investigate the effects of RO5459072 (100\u2009mg twice daily; 200\u2009mg per day). Seventy-five patients with pSS were randomized 1:1 to receive either RO5459072 or placebo for 12\u2009weeks. The primary outcome was the proportion of patients with a \u22653 point reduction from baseline in EULAR SS Disease Activity Index (ESSDAI) score. We also investigated the effects of RO5459072 on quality of life, exocrine gland function, biomarkers related to SS, and safety and tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The proportion of patients showing an improvement in ESSDAI score was not significantly different between the RO5459072 and placebo arms. No clinically meaningful treatment effects were observed in favour of RO5459072 for all secondary outcomes. Analysis of soluble biomarkers indicated target engagement between RO5459072 and cathepsin S. There were modest decreases in the number of circulating B cells and T cells in the RO5459072 group, although these did not reach significance. RO5459072 was safe and well-tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There was no clinically relevant improvement in ESSDAI score (primary endpoint), and no apparent benefit in favour of RO5459072 in any of the secondary clinical endpoints. Further work is needed in order to understand the mechanisms of MHC-II-mediated immune stimulation in pSS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov; NCT02701985.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/kead092","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T09:33:27Z","timestamp":1677663207000},"page":"3644-3653","source":"Crossref","is-referenced-by-count":38,"title":["A randomized, double-blind, placebo-controlled, parallel group study on the effects of a cathepsin S inhibitor in primary Sj\u00f6gren\u2019s syndrome"],"prefix":"10.1093","volume":"62","author":[{"given":"Darren","family":"Bentley","sequence":"first","affiliation":[{"name":"Certara UK Ltd , Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-549X","authenticated-orcid":false,"given":"Benjamin A","family":"Fisher","sequence":"additional","affiliation":[{"name":"Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham , Birmingham, UK"},{"name":"National Institute of Health Research (NIHR) Birmingham Biomedical Research Centre and Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust , Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Barone","sequence":"additional","affiliation":[{"name":"Candel Therapeutics , Needham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice A","family":"Kolb","sequence":"additional","affiliation":[{"name":"Galapagos GmbH , Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Attley","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development , Little Falls, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"key":"2024020515520206000_kead092-B1","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1002\/acr.23173","article-title":"Prevalence of primary Sj\u00f6gren\u2019s syndrome in a US population-based cohort","volume":"69","author":"Maciel","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024020515520206000_kead092-B2","doi-asserted-by":"crossref","first-page":"10627","DOI":"10.1038\/s41598-020-67462-z","article-title":"Prevalence of Sj\u00f6gren\u2019s syndrome in the general adult population in Spain: estimating the proportion of undiagnosed cases","volume":"10","author":"Narv\u00e1ez","year":"2020","journal-title":"Sci Rep"},{"key":"2024020515520206000_kead092-B3","first-page":"247","article-title":"The epidemiology of Sj\u00f6gren\u2019s syndrome","volume":"6","author":"Patel","year":"2014","journal-title":"Clin Epidemiol"},{"key":"2024020515520206000_kead092-B4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7150\/ijms.17718","article-title":"Reviewing primary Sj\u00f6gren\u2019s syndrome: beyond the dryness - from pathophysiology to diagnosis and treatment","volume":"14","author":"Both","year":"2017","journal-title":"Int J Med Sci"},{"key":"2024020515520206000_kead092-B5","doi-asserted-by":"crossref","first-page":"16047","DOI":"10.1038\/nrdp.2016.47","article-title":"Sj\u00f6gren syndrome","volume":"2","author":"Brito-Zer\u00f3n","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 118","key":"2024020515520206000_kead092-B6","first-page":"199","article-title":"Double anti-B cell and anti-BAFF targeting for the treatment of primary Sj\u00f6gren\u2019s syndrome","volume":"37","author":"Gandolfo","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2024020515520206000_kead092-B7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrrheum.2018.1","article-title":"B cells in the pathogenesis of primary Sj\u00f6gren syndrome","volume":"14","author":"Nocturne","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2024020515520206000_kead092-B8","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/nrrheum.2016.100","article-title":"Treatment of primary Sj\u00f6gren syndrome","volume":"12","author":"Saraux","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2024020515520206000_kead092-B9","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/ICO.0000000000001865","article-title":"Sj\u00f6gren\u2019s syndrome: more than just dry eye","volume":"38","author":"Akpek","year":"2019","journal-title":"Cornea"},{"key":"2024020515520206000_kead092-B10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/acr.22968","article-title":"Treatment guidelines for rheumatologic manifestations of Sj\u00f6gren\u2019s syndrome: use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain","volume":"69","author":"Carsons","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024020515520206000_kead092-B11","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1515\/hsz-2015-0114","article-title":"Cathepsin S: therapeutic, diagnostic, and prognostic potential","volume":"396","author":"Wilkinson","year":"2015","journal-title":"Biol Chem"},{"key":"2024020515520206000_kead092-B12","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1038\/s41598-017-01894-y","article-title":"Cathepsin S inhibition combines control of systemic and peripheral pathomechanisms of autoimmune tissue injury","volume":"7","author":"Tato","year":"2017","journal-title":"Sci Rep"},{"key":"2024020515520206000_kead092-B13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bcp.2017.10.001","article-title":"Cathepsin S inhibition suppresses autoimmune-triggered inflammatory responses in macrophages","volume":"146","author":"Thanei","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"2024020515520206000_kead092-B14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1172\/JCI0214682","article-title":"Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity","volume":"110","author":"Saegusa","year":"2002","journal-title":"J Clin Invest"},{"key":"2024020515520206000_kead092-B15","doi-asserted-by":"crossref","first-page":"11044","DOI":"10.1038\/s41598-018-29411-9","article-title":"Increased cathepsin S activity associated with decreased protease inhibitory capacity contributes to altered tear proteins in Sj\u00f6gren\u2019s Syndrome patients","volume":"8","author":"Edman","year":"2018","journal-title":"Sci Rep"},{"key":"2024020515520206000_kead092-B16","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/art.38633","article-title":"Tear cathepsin S as a candidate biomarker for Sj\u00f6gren\u2019s syndrome","volume":"66","author":"Hamm-Alvarez","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2024020515520206000_kead092-B17","doi-asserted-by":"crossref","first-page":"9559","DOI":"10.1038\/s41598-019-45966-7","article-title":"Inhibition of cathepsin S reduces lacrimal gland inflammation and increases tear flow in a mouse model of Sj\u00f6gren\u2019s syndrome","volume":"9","author":"Klinngam","year":"2019","journal-title":"Sci Rep"},{"key":"2024020515520206000_kead092-B18","doi-asserted-by":"crossref","first-page":"9789","DOI":"10.1021\/jm401528k","article-title":"Identification of potent and selective cathepsin S inhibitors containing different central cyclic scaffolds","volume":"56","author":"Hilpert","year":"2013","journal-title":"J Med Chem"},{"key":"2024020515520206000_kead092-B19","doi-asserted-by":"crossref","first-page":"806","DOI":"10.3389\/fimmu.2017.00806","article-title":"Pharmacodynamic monitoring of RO5459072, a small molecule inhibitor of cathepsin S","volume":"8","author":"Theron","year":"2017","journal-title":"Front Immunol"},{"key":"2024020515520206000_kead092-B20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13075-019-1955-2","article-title":"Differential effects of specific cathepsin S inhibition in biocompartments from patients with primary Sj\u00f6gren syndrome","volume":"21","author":"Hargreaves","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2024020515520206000_kead092-B21","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sjogren\u2019s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren\u2019s syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2024020515520206000_kead092-B22","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2013-204615","article-title":"Validation of EULAR primary Sj\u00f6gren\u2019s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)","volume":"74","author":"Seror","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2024020515520206000_kead092-B23","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/annrheumdis-2014-206008","article-title":"Defining disease activity states and clinically meaningful improvement in primary Sj\u00f6gren\u2019s syndrome with EULAR primary Sj\u00f6gren\u2019s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)","volume":"75","author":"Seror","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2024020515520206000_kead092-B24","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sjogren\u2019s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren\u2019s syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2024020515520206000_kead092-B25","first-page":"351","article-title":"Influence of clinical and immunological parameters on the health-related quality of life of patients with primary Sj\u00f6gren\u2019s syndrome","volume":"23","author":"Belenguer","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2024020515520206000_kead092-B26","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0895-4356(98)00081-X","article-title":"Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project","volume":"51","author":"Ware","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"2024020515520206000_kead092-B27","doi-asserted-by":"crossref","first-page":"E125","DOI":"10.1016\/S2665-9913(20)30002-3","article-title":"Is it the end of the road for abatacept treatment in Sj\u00f6gren\u2019s syndrome?","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2024020515520206000_kead092-B28","doi-asserted-by":"crossref","first-page":"e000022","DOI":"10.1136\/rmdopen-2014-000022","article-title":"EULAR Sj\u00f6gren\u2019s syndrome disease activity index (ESSDAI): a user guide","volume":"1","author":"Seror","year":"2015","journal-title":"RMD Open"},{"key":"2024020515520206000_kead092-B29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.7150\/jca.5044","article-title":"Cystatins in immune system","volume":"4","author":"Magister","year":"2013","journal-title":"J Cancer"},{"key":"2024020515520206000_kead092-B30","first-page":"361","article-title":"Normal reference levels of serum cystatin C in Saudi adults","volume":"19","author":"Al Wakeel","year":"2008","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"2024020515520206000_kead092-B31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.rbr.2015.06.004","article-title":"Validation and psychometric properties of the Eular Sj\u00f6gren\u2019s Syndrome Patient Reported Index (ESSPRI) into Brazilian Portuguese","volume":"55","author":"Paganotti","year":"2015","journal-title":"Rev Bras Reumatol"},{"key":"2024020515520206000_kead092-B32","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2020-218599","article-title":"Efficacy and safety of abatacept in active primary Sj\u00f6gren\u2019s syndrome: results of a phase III, randomised, placebo-controlled trial","volume":"80","author":"Baer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024020515520206000_kead092-B33","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"2024020515520206000_kead092-B34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2020-218467","article-title":"Interleukin 6 receptor inhibition in primary Sj\u00f6gren syndrome: a multicentre double-blind randomised placebo-controlled trial","volume":"80","author":"Felten","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024020515520206000_kead092-B35","doi-asserted-by":"crossref","first-page":"E553","DOI":"10.1016\/S2665-9913(21)00122-3","article-title":"Composite of Relevant Endpoints for Sj\u00f6gren\u2019s Syndrome (CRESS): development and validation of a novel outcome measure","volume":"3","author":"Arends","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2024020515520206000_kead092-B36","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2021-222054","article-title":"Development and preliminary validation of the Sj\u00f6gren\u2019s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sj\u00f6gren\u2019s syndrome","volume":"81","author":"Seror","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024020515520206000_kead092-B37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.2014.7682","article-title":"Effects of hydroxychloroquine on symptomatic improvement in primary Sj\u00f6gren syndrome: the JOQUER randomized clinical trial","volume":"312","author":"Gottenberg","year":"2014","journal-title":"JAMA"},{"key":"2024020515520206000_kead092-B38","doi-asserted-by":"crossref","first-page":"e001064","DOI":"10.1136\/rmdopen-2019-001064","article-title":"Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome","volume":"5","author":"Brito-Zer\u00f3n","year":"2019","journal-title":"RMD Open"},{"key":"2024020515520206000_kead092-B39","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"key":"2024020515520206000_kead092-B40","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sj\u00f6gren\u2019s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"D\u00f6rner","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2024020515520206000_kead092-B41","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-CD40 antibody iscalimab in patients with primary Sj\u00f6gren\u2019s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2024020515520206000_kead092-B42","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S2665-9913(20)30057-6","article-title":"Leflunomide\u2013hydroxychloroquine combination therapy in patients with primary Sj\u00f6gren\u2019s syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial","volume":"2","author":"van der Heijden","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2024020515520206000_kead092-B43","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jaut.2011.01.003","article-title":"Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity","volume":"36","author":"Baugh","year":"2011","journal-title":"J Autoimmun"},{"key":"2024020515520206000_kead092-B44","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/annrheumdis-2013-203717","article-title":"Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming","volume":"74","author":"Rupanagudi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2024020515520206000_kead092-B45","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jaad.2021.09.074","article-title":"An open-label phase 2a study investigating the efficacy and safety of a cathepsin S inhibitor in patients with moderate-to-severe psoriasis","volume":"87","author":"Gadola","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2024020515520206000_kead092-B46","author":"EU Clinical Trials Register","year":"2022"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead092\/49512041\/kead092.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/11\/3644\/56585912\/kead092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/11\/3644\/56585912\/kead092.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T10:52:47Z","timestamp":1707130367000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/11\/3644\/7067738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":46,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,3,2]]},"published-print":{"date-parts":[[2023,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead092","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,1]]},"published":{"date-parts":[[2023,3,2]]}}}